Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in CVS Health Co. (NYSE:CVS)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in CVS Health Co. (NYSE:CVS - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 698,845 shares of the pharmacy operator's stock, valued at approximately $31,371,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.06% of CVS Health as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in CVS. McIlrath & Eck LLC grew its holdings in shares of CVS Health by 32.6% in the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after purchasing an additional 174 shares during the last quarter. Coppell Advisory Solutions LLC increased its stake in CVS Health by 17.3% during the 4th quarter. Coppell Advisory Solutions LLC now owns 1,282 shares of the pharmacy operator's stock worth $56,000 after purchasing an additional 189 shares in the last quarter. EagleClaw Capital Managment LLC increased its stake in CVS Health by 3.4% during the 4th quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator's stock worth $275,000 after purchasing an additional 200 shares in the last quarter. Manchester Capital Management LLC grew its stake in shares of CVS Health by 4.8% during the 4th quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator's stock worth $200,000 after acquiring an additional 204 shares in the last quarter. Finally, Angeles Investment Advisors LLC grew its stake in shares of CVS Health by 3.7% during the 4th quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator's stock worth $256,000 after acquiring an additional 204 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Stock Performance

NYSE:CVS traded up $1.21 during mid-day trading on Friday, hitting $63.99. 13,306,917 shares of the company traded hands, compared to its average volume of 11,257,952. The stock's fifty day moving average price is $65.62 and its 200-day moving average price is $59.60. CVS Health Co. has a one year low of $43.56 and a one year high of $72.51. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The firm has a market cap of $80.95 billion, a price-to-earnings ratio of 17.48, a price-to-earnings-growth ratio of 0.98 and a beta of 0.60.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.63. The business had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the company earned $1.31 EPS. Research analysts anticipate that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were given a dividend of $0.665 per share. The ex-dividend date was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 4.16%. CVS Health's dividend payout ratio is currently 63.48%.

Insiders Place Their Bets

In related news, SVP James David Clark sold 7,513 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the transaction, the senior vice president now owns 8,394 shares of the company's stock, valued at approximately $556,941.90. This represents a 47.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.22% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CVS. Cantor Fitzgerald raised CVS Health from a "neutral" rating to an "overweight" rating in a report on Wednesday, February 12th. Royal Bank of Canada boosted their price target on CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a research note on Monday, May 5th. Wall Street Zen raised CVS Health from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Wells Fargo & Company reissued an "overweight" rating and set a $84.00 target price (up previously from $76.00) on shares of CVS Health in a research note on Tuesday, May 6th. Finally, Barclays boosted their price target on CVS Health from $73.00 to $82.00 and gave the stock an "overweight" rating in a report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $74.94.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.